Epidarex

Epidarex Capital – Catalyzing innovation in health science and technology

Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

New designation now includes all PNH patients ​CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that the U.S. Food and…

Epidarex Expands Team

We are pleased to welcome Terri Burke to the Epidarex team.  Terri joins the Epidarex transatlantic team as a Venture Partner and will focus on developing and executing our upcoming funds’ MedTech strategy.  From her base in the U.S., Terri will be sourcing new investment…